Medi Weight Loss Injections: Separating Fact from the Myths

The biggest myth: that these injections work the same way as older weight-loss drugs

A common misunderstanding is that medi weight loss injections are a modern version of older stimulant-based or appetite-suppressant medicines from the 1990s and 2000s. They are not. Tirzepatide and semaglutide belong to an entirely different class. Tirzepatide is a dual GIP and GLP-1 receptor agonist (the only medicine in its class licensed in the UK) meaning it activates two separate gut-hormone pathways involved in appetite regulation and blood-sugar control. Semaglutide (Wegovy) targets GLP-1 receptors alone. Both slow the rate at which food leaves the stomach, which prolongs the feeling of fullness after eating.

The practical result is that people on these treatments tend to eat less without consciously trying to restrict calories. That is a biological mechanism, not willpower. The evidence behind licensed weight loss injections in the UK comes from large, peer-reviewed trials: SURMOUNT-1 recorded an average body-weight reduction of around 20–21% at 15mg tirzepatide over 72 weeks, while STEP 1 recorded around 15% with semaglutide 2.4mg over 68 weeks, both published in the New England Journal of Medicine. These figures are averages from thousands of trial participants under controlled conditions; individual results vary and depend partly on dose reached, lifestyle changes and how consistently the injection is taken.

Both are Black Triangle (▼) medicines, meaning the MHRA requires additional post-marketing surveillance. That does not make them unsafe, it reflects the regulatory standard applied to recently authorised treatments.

Who these injections are actually prescribed for

Licensed eligibility under the UK SmPCs covers adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present, for example, type 2 diabetes, hypertension, high cholesterol or obstructive sleep apnoea. NICE's appraisal of tirzepatide (TA1026) sets higher NHS thresholds alongside phased rollout criteria, but private prescribing follows the licensed eligibility set out in the SmPCs. BMI alone does not determine whether a prescription is appropriate: a prescriber considers your full medical history, current medicines and any contraindications before deciding.

People who are pregnant, breastfeeding, trying to conceive or under 18 are not suitable candidates, these medicines are not licensed for those groups. A history of certain conditions, including medullary thyroid carcinoma or MEN2, also requires careful prescriber discussion. The practical eligibility picture for weight loss injections is broader than the NHS criteria that dominate headlines; many people who do not qualify for NHS access are suitable for private prescription following a proper clinical assessment. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance.

One checking habit worth building before you start any consultation: look up the pharmacy's registration number on the GPhC register. It takes under a minute and tells you immediately whether the service is legitimate. Any seller offering these medicines without a prescription is operating outside UK law.

Injection technique, needles and storage: the practical side most guides skip

The injections are subcutaneous, delivered just under the skin, not into muscle. Licensed sites are the abdomen, outer thigh and upper arm, rotated each week to avoid skin changes at any one spot. The pen is pre-filled; you do not draw up a dose. Each Mounjaro KwikPen contains four weekly doses, while Wegovy uses separate single-dose pens. Treatment begins at the lowest strength (2.5mg for tirzepatide, 0.25mg for semaglutide) and is increased gradually by the prescriber, with the starter dose serving to acclimatise the body rather than as a therapeutic target in itself.

Changing the needle before every injection matters more than it sounds. A needle used twice becomes blunter and increases discomfort and the risk of skin reactions; the right needle for your weight loss injection is a straightforward but often overlooked detail. Cleaning the injection site with an alcohol swab first is standard practice. After each injection, the used pen or needle goes directly into a sharps container, not the household bin.

Both medicines require refrigeration between 2°C and 8°C. There is a limited window during which a pen can be kept at room temperature, the exact duration is set out in the Patient Information Leaflet for each product, and that is the definitive reference, not any summary you read online. If a pen has been left out longer than the leaflet allows, it should not be used.

Side effects are predominantly gastrointestinal: nausea, loose stools, constipation and indigestion are the most commonly reported, particularly after starting or moving to a higher dose. They tend to ease within a couple of weeks for most people. Seek urgent medical attention for severe, persistent abdominal pain that spreads to the back, with or without vomiting, this can be a sign of pancreatitis, a known but infrequent risk the MHRA highlighted in a Drug Safety Update in January 2026. Details of other side effects associated with weight loss medication injections are covered in the relevant NHS guidance.

Curious about the broader range of options? The weight loss treatments available through nume are set out on the treatment page, alongside how the weight loss med injection consultation process works.